Atosiban is a peptide oxytocin receptor (OTR) antagonist. Atosiban has a specific mode of action, inhibiting oxytocin-induced uterine contractions by blocking oxytocin receptors in the uterus. Extensive clinical investigations have shown Atosiban to be at least as effective as current tocolytic agents in the treatment of preterm labor. In addition, due to its novel and specific mode of action, Atosiban has a markedly improved maternal side effects profile compared with conventional therapies.
Atosiban has a molecular formula of C43H67N11O12S2, 3-Mercaptopropionyl-D-Tyr(ET)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2 and a molecular weight of 994.2 Dalton.
CAS Registry Number
CAS No. 90779-69-4
Greater than 98.0% as determined by RP-HPLC.
Sterile filtered white lyophilized (freeze-dried) powder. The Atosiban was lyophilized with no additives.
It is recommended to reconstitute the lyophilized Atosiban in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
At ambient temperature. Upon receipt, store at the temperature recommended below.
Lyophilized Atosiban, although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution, Atosiban should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
This product is intended for Laboratory Research Use Only. Not for use in diagnostic or therapeutic procedures. This product may not be used as a pharmaceutical or veterinary drug, agricultural product, or food additive.